Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Celgene Corporation
Current Parent Company: Bristol-Myers Squibb
Penalty: $34,000,000
Year: 2020
Date: October 2, 2020
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: Celgene agreed to pay $34 million to settle litigation alleging it monopolized and blocked generic alternatives to the cancer medications Thalomid and Revlimid.
Level of Government: federal
Action Type: private litigation
Court: District of New Jersey
Civil or Criminal Case: civil
Case ID: 2:14cv6997
Case Name: International Union of Bricklayers and Allied Craft Workers Local 1 Health Fund v. Celgene Corporation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: New York
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.